Epidyolex (also known as Epidiolex) is a licensed cannabidiol (CBD) oil, originally developed by GW Pharmaceuticals (now part of Jazz Pharmaceuticals). The spelling differs by region: Epidiolex in the US and Epidyolex in Europe, including the UK.
It is the only CBD-only medical cannabis medicine currently available on the NHS, with prescribing limited to certain patients. Epidyolex is taken orally as a solution and is licensed for adults and children with severe, drug-resistant epilepsy — specifically Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex (when used alongside clobazam).
